Stocks to Watch: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD),

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from a Phase 1b clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer. The Phase 1b dose-escalation trial enrolled 27 previously untreated patients with extensive-stage small cell lung cancer to assess the safety, biomarker, and anti-tumor activity of tarextumab in combination with etoposide and platinum-based chemotherapy. Doses of tarextumab ranged from 5 mg/kg to 15 mg/kg and a Phase 2 combination dose of 15mg/kg every three weeks was selected.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) belongs to Healthcare sector. Its weekly performance is 4.64%. On last trading day company shares ended up at $9.92.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported net income of $17.0 million, compared to a net loss of $21.6 million in the three months ended December 31, 2014. For the full year ended December 31, 2015, the Company’s net loss was $5.0 million, or $0.04 per share, compared to a net loss of $69.0 million for the year ended December 31, 2014, or $0.70 per share. Cash, cash equivalents, marketable securities, and interest receivable at December 31, 2015 were $460.5 million.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares moved up 7.30% in last trading session and ended the day at $7.35. ACHN return on assets is -14.80%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) quarterly performance is -25.98%.

On 23 February, Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) reported revenue of $222.6 million, net loss from continuing operations of $0.8 million and Adjusted EBITDA from continuing operations of $22.2 million. For the year ended December 31, 2015, Great Lakes reported revenue of $856.9 million, net loss from continuing operations of $6.2 million and Adjusted EBITDA from continuing operations of $83.0 million.

On 26 February, Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) shares moved down -1.19% and was closed at $3.32. GLDD EPS growth in last 5 year was -18.60%. Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) year to date (YTD) performance is -16.16%.

Bristol-Myers Squibb Company (NYSE:BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Opdivo (nivolumab) for two new indications – adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, and adults with advanced renal cell carcinoma (RCC) after prior therapy. Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care.

Bristol-Myers Squibb Company (NYSE:BMY) ended the last trading day at $62.25. Company weekly volatility is calculated as 1.95% and price to cash ratio as 24.34. Bristol-Myers Squibb Company (NYSE:BMY) showed a weekly performance of -2.43%.

On 24 February, Nanosphere, Inc. (NASDAQ:NSPH) reported Net loss for the fourth quarter of 2015 was $5.7 million compared with $9.5 million for the same period in 2014. Net loss in 2015 was $30.6 million, compared with $39.1 million in 2014. Cash at December 31, 2015 was $19.1 million, with $4 million of this being restricted cash. Cash used in operations during the fourth quarter of 2015 was $5.0 million, compared to $8.6 million for the same period in 2014, an improvement of $3.6 million.

Nanosphere, Inc. (NASDAQ:NSPH) shares moved down -1.10% in last trading session and ended the day at $0.72. NSPH Gross Margin is 40.70% and its return on assets is -102.70%. Nanosphere, Inc. (NASDAQ:NSPH) quarterly performance is -42.70%.

Leave a Reply

Your email address will not be published. Required fields are marked *